Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations Journal Article
| Authors: | Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S.; Yellapantula, V.; Famulare, C.; Argyropoulos, K.; Derkach, A.; Papaemmanuil, E.; Dogan, A.; Lesokhin, A.; Usmani, S. Z.; Landgren, C. O.; Palomba, L. M.; Maura, F.; Dimopoulos, M. A. |
| Article Title: | Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations |
| Abstract: | The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by somatic mutations in MYD88, present from the precursor stages. Using the comprehensive resolution of whole genome sequencing (WGS) in 14 CD19-selected primary WM samples; comparing clonal and subclonal mutations revealed that germinal center (GC) mutational signatures SBS9 (poly-eta) and SBS84 (AID) have sustained activity, suggesting that the interaction betweenWMand the GC continues over time. Expanding our cohort size with 33 targeted sequencing samples, we interrogated the WM copy number aberration (CNA) landscape and chronology. Of interest, CNA prevalence progressively increased in symptomatic WM and relapsed disease when compared with stable precursor stages, with stable precursors lacking genomic complexity. Two MYD88 wild-type WGS contained a clonal gain affecting chromosome 12, which is typically an early event in chronic lymphocytic leukemia. Molecular time analysis demonstrated that both chromosomal 12 gain events occurred early in cancer development whereas other CNA changes tend to occur later in the disease course and are often subclonal. In summary, WGS analysis in WM allows the demonstration of sustained GC activity over time and allows the reconstruction of the temporal evolution of specific genomic features. In addition, our data suggest that, although MYD88-mutations are central to WM clone establishment and can be observed in precursor disease, CNA may contribute to later phases, and may be used as a biomarker for progression risk from precursor conditions to symptomatic disease. © 2023 by The American Society of Hematology. |
| Journal Title: | Blood Advances |
| Volume: | 7 |
| Issue: | 6 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-03-28 |
| Start Page: | 971 |
| End Page: | 981 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2022008876 |
| PUBMED: | 36332058 |
| PROVIDER: | scopus |
| PMCID: | PMC10027506 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and publisher record. Corresponding author is MSK author Francesco Maura -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
442Palomba -
374Lesokhin -
47Argyropoulos -
469Dogan -
88Famulare -
213Papaemmanuil -
155Maclachlan -
169Derkach -
327Usmani
Related MSK Work